Diagenode

TIP60: an actor in acetylation of H3K4 and tumor development in breast cancer.


Judes G, Dubois L, Rifaï K, Idrissou M, Mishellany F, Pajon A, Besse S, Daures M, Degoul F, Bignon YJ, Penault-Llorca F, Bernard-Gallon D

AIM: The acetyltransferase TIP60 is reported to be downregulated in several cancers, in particular breast cancer, but the molecular mechanisms resulting from its alteration are still unclear. MATERIALS & METHODS: In breast tumors, H3K4ac enrichment and its link with TIP60 were evaluated by chromatin immunoprecipitation-qPCR and re-chromatin immunoprecipitation techniques. To assess the biological roles of TIP60 in breast cancer, two cell lines of breast cancer, MDA-MB-231 (ER-) and MCF-7 (ER+) were transfected with shRNA specifically targeting TIP60 and injected to athymic Balb-c mice. RESULTS: We identified a potential target of TIP60, H3K4. We show that an underexpression of TIP60 could contribute to a reduction of H3K4 acetylation in breast cancer. An increase in tumor development was noted in sh-TIP60 MDA-MB-231 xenografts and a slowdown of tumor growth in sh-TIP60 MCF-7 xenografts. CONCLUSION: This is evidence that the underexpression of TIP60 observed in breast cancer can promote the tumorigenesis of ER-negative tumors.

Tags
IP-Star Compact

Share this article

Published
November, 2018

Source

Products used in this publication

  • Antibody ChIP-seq grade icon
    C15410069
    H3K27me3 polyclonal antibody - Classic
  • Antibody ChIP icon
    C15410165
    H3K4ac polyclonal antibody - Classic
  • Antibody ChIP-seq grade icon
    C15410056
    H3K9me3 polyclonal antibody
  • RFX5-polyclonal-antibody-diagenode
    C15410206
    Rabbit IgG
  • some alt
    B03000002
    SX-8G IP-Star® Compact Automated System

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics